Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2022-05-04 Board/Management Inform…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 8K/A, AMENDMENT #1
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. The content specifically addresses a correction related to the vesting date of options granted to an officer, which falls under the category of changes in directors or officers. The document is short (3418 characters) and is an amendment to a current report about management changes, not a full financial report or earnings release. Therefore, it fits best under Board/Management Information (MANG).
2022-05-04 English
FORM 8K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure and appointment of a director/officer, including the CEO's employment terms, salary, bonuses, stock options, and severance conditions. This matches the description of announcements related to changes in the company's board of directors or senior management. There is no financial statement or earnings data, so it is not an earnings release or financial report. The document is not a proxy statement, merger filing, or other categories. Therefore, the best fit is Board/Management Information (MANG). The confidence is high given the clear focus on management changes and compensation terms.
2022-05-02 English
FORM 8K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 25, 2022. It reports the submission of matters to a vote of security holders at the Annual Meeting of Stockholders, including election of board members, approval of executive compensation (Say-on-Pay), and ratification of the independent auditor. The content focuses on voting results from the shareholder meeting. The document length is 4065 characters, which is relatively short and consistent with a voting results announcement rather than a full annual report or other detailed filings. The key section is Item 5.07, which specifically relates to submission of matters to a vote of security holders. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the correct classification is DVA with high confidence.
2022-04-29 English
FORM 4
Director's Dealing
2022-04-28 English
FORM 4
Director's Dealing
2022-04-28 English
FORM 4
Director's Dealing
2022-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.